Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Patiromer for hyperkalaemia – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Patiromer is intended for the treatment of acute and/or chronic hyperkalaemia in patients with chronic kidney disease, type 2 diabetes or chronic heart failure. If licensed, patiromer will offer a novel treatment option for hyperkalaemia in this patient group who currently have few well-tolerated effective therapies available. Patiromer is a non-absorbed cation-exchange polymer that binds potassium predominantly in the lumen of the colon where potassium is the most abundant cation. Patiromer does not currently have Marketing Authorisation in the EU for any indication.
The incidence of hyperkalaemia varies between 1.1% and 10% of hospital patients, of which 77% of cases are thought to be due to renal failure, 63% to prescribed drugs, and 49% to hyperglycaemia. Hyperkalaemia is the reason for emergency haemodialysis in 24% of haemodialysis patients and accounts for 3-5% of deaths in this patient group. In 2013-14, there were 7,214 hospital admissions for hyperkalaemia in England, resulting in 20,725 bed days and 9,942 finished consultant episodes.
There is limited good quality evidence on the role of drug treatment in hyperkalaemia. Aside from reducing potassium intake, treatment options largely focus on reducing cardiac cell membrane excitability, shifting of potassium from the extracellular to the intracellular domain and reducing total body potassium. Patiromer has completed a phase III clinical trial comparing its effect on serum potassium against treatment with placebo. Indexing Status Subject indexing assigned by CRD MeSH Humans; Hyperkalemia; Polymers; Potassium Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000368 Date abstract record published 04/03/2016 |